MatrixCare vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Senior living and long-term care management software for skilled nursing, assisted living, and home health organizations. Minneapolis, MN. Acquired by ResMed.
About
MatrixCare is a Minneapolis, Minnesota-based provider of electronic health record and business management software for the senior living and post-acute care market. Acquired by ResMed (NYSE: RMD) in 2018, MatrixCare operates as ResMed's long-term care software division and serves over 15,000 care settings across skilled nursing facilities, senior living communities, home health agencies, and hospice providers. The platform provides EHR, billing, scheduling, and analytics capabilities designed for the clinical and operational complexity of long-term care.\n\nMatrixCare's product suite includes separate but integrated modules for skilled nursing, senior living (assisted living and memory care), home health, and hospice care, reflecting the different clinical workflows and regulatory requirements across these settings. The skilled nursing module addresses Medicare and Medicaid billing complexity, MDS documentation, and therapy management. The senior living module focuses on activity of daily living documentation, resident assessment tracking, and billing for private-pay and Medicaid waiver programs.\n\nResMed's acquisition of MatrixCare reflected the strategic importance of care coordination between home-based care (ResMed's core sleep therapy and respiratory device business) and facility-based post-acute care. The combined organization can offer integrated monitoring data from connected medical devices alongside clinical documentation in the EHR, positioning MatrixCare within ResMed's broader digital health strategy. MatrixCare competes directly with PointClickCare as the two dominant EHR platforms in the North American LTPAC market.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.